{"meta":{"totalResults":3,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Revlimid"},{"type":"Synonym","name":"IMiD-1"},{"type":"CodeName","name":"CC-5013"},{"type":"LexicalVariant","name":"CC5013"},{"type":"CodeName","name":"CDC 501"},{"type":"CASRegistryName","name":"191732-72-6"},{"type":"ChemicalStructureName","name":"3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione"}],"definition":{"html":"A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","text":"A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/lenalidomide","text":"Lenalidomide"},"nciConceptId":"C2668","nciConceptName":"Lenalidomide","termId":38564,"name":"lenalidomide","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lenalidomide"},{"aliases":[{"type":"CodeName","name":"KPG 121"},{"type":"CodeName","name":"KPG-121"},{"type":"CodeName","name":"KPG121"}],"definition":{"html":"A lenalidomide analog with potential anti-angiogenic and immunomodulatory activities. Upon oral administration, lenalidomide analog KPG-121 may inhibit tumor necrosis factor alpha (TNF-alpha) production, stimulate T-lymphocytes, reduce serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibit angiogenesis. Additionally, KPG-121 may promote G1 cell cycle arrest and induce apoptosis in malignant cells.","text":"A lenalidomide analog with potential anti-angiogenic and immunomodulatory activities. Upon oral administration, lenalidomide analog KPG-121 may inhibit tumor necrosis factor alpha (TNF-alpha) production, stimulate T-lymphocytes, reduce serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibit angiogenesis. Additionally, KPG-121 may promote G1 cell cycle arrest and induce apoptosis in malignant cells."},"drugInfoSummaryLink":null,"nciConceptId":"C162878","nciConceptName":"Lenalidomide Analog KPG-121","termId":798954,"name":"lenalidomide analog KPG-121","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lenalidomide-analog-kpg-121"},{"aliases":[{"type":"Synonym","name":"lenalidomide long-acting formulation NEX-20A"},{"type":"CodeName","name":"NEX-20A"},{"type":"CodeName","name":"NEX20A"},{"type":"CodeName","name":"NEX 20A"}],"definition":{"html":"A prolonged-release formulation composed of a suspension of the thalidomide analog lenalidomide coated with slow-dissolving nontoxic inorganic oxides, with potential antineoplastic activity. Upon administration via subcutaneous injection, the coating dissolves and lenalidomide is released. Lenalidomide inhibits tumor necrosis factor alpha (TNF-alpha) production, stimulates T lymphocytes, reduces serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibits angiogenesis. Additionally, lenalidomide promotes G1 cell cycle arrest and induces apoptosis in malignant cells.","text":"A prolonged-release formulation composed of a suspension of the thalidomide analog lenalidomide coated with slow-dissolving nontoxic inorganic oxides, with potential antineoplastic activity. Upon administration via subcutaneous injection, the coating dissolves and lenalidomide is released. Lenalidomide inhibits tumor necrosis factor alpha (TNF-alpha) production, stimulates T lymphocytes, reduces serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibits angiogenesis. Additionally, lenalidomide promotes G1 cell cycle arrest and induces apoptosis in malignant cells."},"drugInfoSummaryLink":null,"nciConceptId":"C198985","nciConceptName":"Lenalidomide Prolonged-release Formulation NEX-20A","termId":812187,"name":"lenalidomide prolonged-release formulation NEX-20A","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lenalidomide-prolonged-release-formulation-nex-20a"}],"links":null}